AstraZeneca's Wainua Fails in ATTR-Cardiomyopathy, Ceding Ground to Stabilizers and Raising Class-Wide Risk for Gene Silencers

AstraZeneca's Pipeline Faces Setbacks, M&A Strategy Unchanged

AstraZeneca's CEO Pascal Soriot affirmed the company is on track to achieve its $80 billion revenue goal by 2030, despite the recent late-stage failure of Wainua in a Phase 3 ATTR-cardiomyopathy study. CFO Aradhana Sarin stated this setback does not impact their M&A strategy, viewing it as a normal part of drug development. The company also reported other clinical disappointments, including Ultomiris in thrombotic microangiopathy and an Imfinzi combination in NSCLC. AstraZeneca posted nearly $15.4 billion in Q2 revenues, a 5% year-on-year increase, driven by its oncology and rare disease portfolios.

• The antisense therapy Wainua, developed in partnership with Ionis Pharmaceuticals, failed its Phase 3 CARDIO-TTRansform trial for ATTR-cardiomyopathy. Wainua, a transthyretin silencer, was previously approved in December 2023 for ATTR-polyneuropathy, and its expansion into cardiomyopathy was considered a crucial contributor to AstraZeneca's 2030 revenue target.
• AstraZeneca disclosed additional clinical disappointments, including Ultomiris failing to significantly improve event-free survival in the Phase 3 ALXN1210-TMA-313 trial for thrombotic microangiopathy. The Phase 3 PACIFIC-8 trial for Imfinzi plus an anti-TIGIT antibody in non-small cell lung cancer was discontinued, and sonesitatug vedotin met only one primary efficacy endpoint in the CLARITY-Gastric01 trial for gastric cancer.
• AstraZeneca reported Q2 revenues of nearly $15.4 billion, marking a 5% year-on-year increase at constant currencies. This growth was primarily fueled by its oncology portfolio, which surged 15% to $7.3 billion, and its rare disease unit, which grew 8% to $2.4 billion. Top-selling products included Tagrisso and Imfinzi, both generating $1.9 billion in revenue.
• Despite the pipeline setbacks, CEO Pascal Soriot and CFO Aradhana Sarin reiterated that the failures do not impact AstraZeneca's M&A strategy or its confidence in reaching the $80 billion revenue target by 2030. They emphasized the expansive pipeline and the inherent risks of drug development, asserting that M&A is not essential for achieving their goals.

Wainua's Phase 3 CARDIO-TTRansform Trial: A Setback in ATTR-CM

The therapeutic landscape for ATTR-CM has been defined by transthyretin (TTR) stabilizers, beginning with tafamidis, which was approved following the pivotal ATTR-ACT trial. In that study, tafamidis demonstrated a significant reduction in all-cause mortality at 30 months compared to placebo (HR 0.70; 95% CI 0.51–0.96), establishing the first disease-modifying therapy for the condition. More recently, the field has advanced with acoramidis, a highly potent TTR stabilizer designed to mimic the stabilizing T119M mutation. The Phase 3 ATTRibute-CM trial showed that acoramidis significantly reduced a composite of cardiovascular mortality or first cardiovascular-related hospitalization versus placebo (HR 0.62; 95% CI 0.48-0.80), with early increases in serum TTR levels correlating with improved clinical outcomes.

A distinct therapeutic class, TTR gene silencers, has also proven effective through an alternative mechanism of reducing TTR protein production. In the HELIOS-B trial, the siRNA vutrisiran significantly reduced the primary composite endpoint of all-cause mortality and recurrent cardiovascular events compared to placebo (HR 0.72; 95% CI 0.56-0.93). Beyond hard outcomes, vutrisiran demonstrated beneficial effects on cardiac structure, attenuating declines in ventricular systolic function over 30 months. However, a 2025 meta-analysis suggested that while both stabilizers and silencers improve functional capacity and quality of life, only TTR stabilizers have so far demonstrated a statistically significant reduction in all-cause mortality (RR 0.71), a finding potentially influenced by shorter follow-up durations in the silencer trials. This evolving evidence base exists within a context of changing trial populations, where patients are now enrolled with less advanced disease, reflected by a decline in placebo-group mortality rates from 9.0% in ATTR-ACT to approximately 4.3-5.5% in HELIOS-B.

Navigating the Challenges in ATTR-Cardiomyopathy Treatment

Despite meaningful therapeutic advances, ATTR-CM remains a difficult condition to manage effectively across the diagnostic and treatment continuum. Barriers span delayed recognition, restricted treatment options, high costs, and persistent morbidity even among treated patients, underscoring the need for earlier diagnosis and expanded therapeutic access.

• Diagnostic delay and underrecognition: ATTR-CM has historically been underdiagnosed due to low disease awareness, perceived rarity, and the prior requirement for histological confirmation, frequently resulting in late-stage diagnosis, incorrect management, and poor outcomes.

• Narrow therapeutic window for efficacy: Most disease-modifying therapies, including tafamidis, are most effective when initiated early; delayed diagnosis reduces the survival and functional benefits achievable with treatment, as timely diagnosis (<12 months) has been shown to significantly reduce all-cause mortality (HR 0.29) and prolong MACE-free survival.

• Limited approved treatment options: Tafamidis remains the only approved therapy for ATTR-CM, and its restricted availability—driven by cost and access barriers—highlights the ongoing need for alternative or adjunct therapies despite a growing clinical pipeline.

• Historical lack of effective interventions: Prior to recent approvals, management was largely supportive, with standard heart failure medications often proving ineffective or even harmful due to the difficulty of balancing elevated filling pressures against restricted ventricular volume and low cardiac output; treatment options were essentially limited to heart or liver transplantation, with poor associated prognosis.

• Persistent morbidity and mortality despite treatment: Even with disease-modifying therapy, a substantial proportion of patients continue to experience clinical, biomarker, functional, or quality-of-life decline (69% showing progression in at least one domain), emphasizing the need for better risk stratification and monitoring of treatment response.

• Cost and access constraints: The high cost of newer therapies presents a barrier to sustained treatment, particularly given the relatively small ATTR-CM patient population, complicating both drug development economics and equitable patient access.

• Complex clinical decision-making: With an expanding array of therapeutic options, clinicians face new challenges in selecting appropriate first-line therapy, determining when to switch or combine treatments, and establishing standardized approaches to monitor long-term treatment response.

• Diagnostic infrastructure disparities: Significant global heterogeneity exists in access to and performance of cardiac amyloid radionuclide imaging (CARI), compounded by a lack of standardized protocols, insufficient clinician education, unclear screening guidance for high-risk populations, and the absence of international registries.

• Unmet need in HFpEF management: Progress in treating the heart failure with preserved ejection fraction phenotype common in ATTR-CM remains slow; while ARNIs and SGLT2 inhibitors show promise, dedicated evidence in this population is still emerging.

The ATTR-CM Landscape: Impact on Wainua's MoA and Competitors

Wainua (vutrisiran) is a prominent RNA interference (RNAi) therapeutic that reduces hepatic production of transthyretin (TTR) for treating ATTR amyloidosis. The competitive landscape for this indication includes other gene-silencing therapies that utilize similar mechanisms, specifically RNAi and antisense oligonucleotides (ASO), to inhibit TTR synthesis. The design of the pivotal clinical trials for these agents provides insight into the established development and regulatory pathways.